First Trust標普500經濟護城河ETF EMOT 深 滬
已收盤 02-06 16:00:00 美东时间
25.0117
+0.415
+1.69%
華盛通- 最 高25.0117
- 今 開24.94
- 成交量 437股
- 最 低 24.94
- 昨 收 24.5968
- 總市值 250.12万
- 52周最高 25.0117
- 市盈率 靜 --
- 換手率 0.44%
- 52周最低 18.3597
- 委 比 0.00%
- 總股本 10.00万
- 歷史最高 25.0117
- 量 比 0.28
- 振 幅 0.29%
- 歷史最低 18.3597
- 每 手 1
- 風險率 1.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-ImmunityBio Launches Phase 2 Chemotherapy-Free Car-Nk Cell Therapy Trial With Anktiva
BRIEF-ImmunityBio Launches Phase 2 Chemotherapy-Free Car-Nk Cell Therapy Trial With Anktiva Feb 2 (Reuters) - Immunitybio Inc IBRX.O : IMMUNITYBIO LAUNCHES PHASE 2 CHEMOTHERAPY-FREE CAR-NK CELL THERAPY TRIAL WITH ANKTIVA® (RESQ215B) IN INDOLENT LYMPHOMAS Source text: ID:nBw3FxXx7a Further company co
02-02 21:03
美股异动 | 特斯拉大涨超4%股价逼近一年高位！AI概念股再度走弱，甲骨文、博通跌超2%
特斯拉大涨超4%逼近一年高位！马斯克称正在测试无人驾驶出租车；AI概念股再度走弱，甲骨文、博通跌超2%，现在服务重挫8%>>
2025-12-15 22:42
BRIEF-Merck And Eisai Provide Update On Phase 3 Leap-015 Trial
Jan 24 (Reuters) - Merck & Co Inc MRK.N: MERCK AND EISAI PROVIDE UPDATE ON PHASE 3 LEAP-015 TRIAL EVALUATING KEYTRUDA® (PEMBROLIZUMAB) PLUS LENVIMA® (LENVATINIB) IN COMBINATION WITH CHEMOTHERAPY IN PA...
2025-01-24 20:26
BRIEF-Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
Jan 15 (Reuters) - Zai Lab Ltd 9688.HK: ZAI LAB ANNOUNCES POSITIVE TOPLINE RESULTS FOR TIVDAK IN THE CHINA SUBPOPULATION OF THE GLOBAL PHASE 3 INNOVATV 301 TRIAL IN PATIENTS WITH RECURRENT OR METASTAT...
2025-01-15 21:07
